JAK1-IN-11
JAK1-IN-11 (compound 11) is a potent inhibitor of JAK, with IC50s of 0.02 nM (JAK1), and 0.44 nM (JAK2), respectively. JAK1-IN-11 has high selectivity against JAK1 over JAK2[1].
Product Specifications
CAS Number
2427608-43-1
UNSPSC
12352005
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jak1-in-11.html
Purity
98.27
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C[C@@H](O)C1=NC2=CNC3=NC=CC3=C2N1N(CC4)CCC4CNS(C[C@@]56C(C)(C)[C@@](CC6)([H])CC5=O)(=O)=O
Molecular Formula
C26H36N6O4S
Molecular Weight
528.67
References & Citations
[1]Shen W. et al. Amide or sulfonamide substituted hydrazine derivative applied as JAK kinase inhibitor. China, CN110724142 A. 2020-01-24.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Pmel17 / gp100 / SILV (NKI-beteb), CF640R conjugate, 0.1mg/mL
EGFRvIII (Epidermal Growth Factor Receptor, Variant III) (GFR/2600R), CF647 conjugate, 0.1mg/mL
Caldesmon, HMW (h-Caldesmon) (h-CALD), CF647 conjugate, 0.1mg/mL
Renal Cell Carcinoma (Carbonic Anhydrase IX) (CA9/2993R), CF405S conjugate, 0.1mg/mL
MMP9 (MMP9/2025R), CF488A conjugate, 0.1mg/mL
